Indiana University Health’s 70,000-square-foot pharmacy hub and distribution center in Plainfield has enough pills, lotions, and infusible and injectable drugs under one roof to supply its 16 hospitals and hundreds of clinics for weeks.
The fallout from a Pfizer factory being damaged by a tornado could put even more pressure on already-strained drug supplies at U.S. hospitals, experts say.
If U.S. regulators approve, the drug would be only the second Alzheimer’s treatment convincingly shown to delay the mind-robbing disease—after rival Leqembi. Both drugs pose a serious safety concern—brain swelling and bleeding.
More than 110,000 Hoosiers suffer from Alzheimer’s disease, which robs people of their memories and abilities to do daily tasks, and is the nation’s sixth-leading cause of death.
With the acquisition of Versanis Bio, Lilly is adding another promising treatment to its weight-loss drug pipeline.
Women’s health advocates hope the decision will pave the way for more over-the-counter birth control options.
In this week’s edition of the IBJ Podcast, reporter John Russell discusses Medicare’s new power to negotiate drug prices and its effects on patients, drug makers and the rest the health care industry. Eli Lilly and Co. would like to see some changes.
David Ricks, CEO of Indianapolis-based drugmaker Eli Lilly and Co., is turning up the volume on his concerns over a new law that would allow Medicare, for the first time, to negotiate drug prices.
Medical experts predict the pills will be popular, especially among people who want to lose weight but are fearful of needles.
The New Jersey-based company has announced two large rounds of layoffs at its Bloomington plant within six months—400 workers last December and 150 this month.
A growing roster of corporate and political foes has started to lay siege to the law, hoping to erode some of its key provisions before they can take effect.
This year is the second year Indiana has received money from a national settlement with opioid distributors and manufacturers for opioid-related harms.
Indianapolis-based Elevance Health, which operates Anthem plans, said that in most cases, it won’t cover Ozempic unless a patient is diagnosed with diabetes and has tried another medication to manage it, but physicians can still prescribe it.
The Indianapolis-based pharmaceutical giant is spending hundreds of millions of dollars to win over patients with an extensive advertising campaign.
Groups such as the Alzheimer’s Association have pushed Medicare to cover the new Alzheimer’s drugs—including those cleared on an expedited basis—saying that the FDA should be the final arbiter of safety and efficacy of drugs.
Under the agreement, Lilly has agreed to continue its cap on out-of-pocket costs for its users at $35 a month for four years.
The Indianapolis-based radiopharmaceutical company said it plans to help open a facility in Belgium to make therapeutic agents for cancer patients.
Senate Enrolled Act 8 is part of a sweeping effort this year by the Indiana General Assembly to bring down the cost of health care across the state, where prices are among the highest in the country.
Eli Lilly and Co. shares have soared 57% over the past 52 weeks, buoyed in part by sales of its diabetes drug Mounjaro, which the company is also preparing to seek approval to market for obesity.
If approved, Donanemab has annual multi-billion-dollar sales potential. Lilly shares rose 6% in early-afternoon trading.
